Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 12 Aug 2024 |
| Orion Group Half-Year Financial Report January-June 2024 | 8 Aug 2024 |
| Orion Corporation's financial reporting and Annual General Meeting in 2025 | 8 Aug 2024 |
| Orion publishes Half-Year Financial Report for January-June 2024 and holds a webcast on 8 August 2024 | 25 Jul 2024 |
| Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint | 17 Jul 2024 |